Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660408 · ClinicalTrials.gov registry record · Phase 1
RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors
A Phase 1 study of Recurrent High Grade Glioma and Recurrent Pulmonary Osteosarcoma, sponsored by University of Florida.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05660408 is a Phase 1 study of Recurrent High Grade Glioma and Recurrent Pulmonary Osteosarcoma that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 36 participants, above the 28-participant average among 4 other Recurrent High Grade Glioma trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05660408, a Phase 1 study of Recurrent High Grade Glioma and Recurrent Pulmonary Osteosarcoma, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The Investigators have demonstrated in preclinical studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of this approach in preclinical models and in canine patients with a spontaneous malignant glioma. In one arm of this study, we will investigate the safety and immunologic activity of RNA-LP vaccines in pediatric patients with recurrent pHGG. The investigators have also shown that intravenous administration of tumor mRNA loaded lipid particles (LPs) localizes primarily to lung, transfect antigen presenting cells (APCs) and lead to an activated T cell response for induction of anti-tumor immunity. In contrast to other formulations, RNA-LPs recruit multiple arms of the immune system (i.e. innate/adaptive), and remodel the systemic/intratumoral immune milieu, which remain potent barriers for vaccine, cellular, and checkpoint inhibiting immunotherapies. After only a single RNA-LP vaccine, the bulk of systemic and intratumoral dendritic cells (DCs) in mice display an activated phenotype; these activated DCs (harvested from tumors) expand antigen specific T cell immunity. In immunologically resistant pulmonary osteosacroma murine tumor models (i.e. K7M2), RNA-LPs induce robust anti-tumor efficacy in settings where immune checkpoint inhibitors (i.e. anti-PD-L1 therapy) do not confer therapeutic benefit. The investigators have already demonstrated safety of RNA-LPs in acute/chronic murine toxicity studies, and in client-owned canine trial. In this study, we will investigate the manufacturing feasibility, safety and immunologic activity of RNA-LP vaccine in patients with recurrent pulmonary or unresectable osteosarcoma and recurrent pHGG.
Conditions Studied
Interventions
- BIOLOGICAL pp65 RNA LP (DP1)
- BIOLOGICAL pp65/tumor mRNA RNA-LP (DP2)
- PROCEDURE Surgical Biopsy/Resection
Study Locations (1)
Florida
- UF Health - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2035-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05660408
The ClinicalTrials.gov registry entry for NCT05660408 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 28-participant average among 4 other Recurrent High Grade Glioma trials with a reported enrollment target (29% higher). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent High Grade Glioma appearing as the primary indexed condition, and to 3 interventions - of which pp65 RNA LP (DP1) is the first listed.
NCT05660408 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05660408 about?
NCT05660408 is a clinical study titled "RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors". The Investigators have demonstrated in preclinical studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of this approach in preclinical models and in canine patients with a spon...
What is the current status of trial NCT05660408?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-03-12. Estimated completion is 2035-10.
What conditions does trial NCT05660408 study?
This clinical trial studies the following conditions: Recurrent High Grade Glioma, Recurrent Pulmonary Osteosarcoma.
What interventions are being tested in trial NCT05660408?
The interventions under investigation include: pp65 RNA LP (DP1) (BIOLOGICAL), pp65/tumor mRNA RNA-LP (DP2) (BIOLOGICAL), Surgical Biopsy/Resection (PROCEDURE).
Who is sponsoring clinical trial NCT05660408?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05660408 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
RECRUITING · Phase 1
-
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
RECRUITING · Phase 1
-
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RECRUITING · Phase 1
-
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.